Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment

被引:0
作者
Jordi, Bruix [1 ]
Philippe, Merle [2 ]
Alessandro, Granito [3 ]
Huang Yi-Hsiang [4 ]
Gyorgy, Bodoky [5 ]
Osamu, Yokosuka [6 ]
Olivier, Rosmorduc [7 ,8 ]
Valeriy, Breder [9 ]
Rene, Gerolami [10 ]
Gianluca, Masi [11 ]
Ross, Paul J. [12 ]
Qin Shukui [13 ]
Song Tianqiang [14 ]
Jean-Pierre, Bronowicki [15 ]
Isabelle, Ollivier-Hourmand [16 ]
Masatoshi, Kudo [17 ]
Marie-Aude, LeBerre [18 ]
Annette, Baumhauer [19 ]
Gerold, Meinhardt [20 ]
Han Guohong [21 ]
机构
[1] Univ Barcelona, Hosp Clin, BCLC Grp, Liver Unit, Barcelona, Spain
[2] Grp Hosp Lyon Nord, Hepatol Unit, Lyon, France
[3] Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Bologna, Italy
[4] Natl Yang Ming Univ, Inst Clin Med, Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan
[5] St Laszl Teaching Hosp, Budapest, Hungary
[6] Chiba Univ, Dept Gastroenterol & Nephrol, Chiba, Japan
[7] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Dept Hepatol, Paris, France
[8] Sorbonne Univ, Univ Pierre & Marie Curie, Paris, France
[9] Russian Canc Res Ctr, Moscow, Russia
[10] Univ La Mediterranee, CHU Timone, Marseille, France
[11] Azienda Osped Univ Pisana, Pisa, Italy
[12] Kings Coll Hosp NHS Fdn Trust, London, England
[13] Nanjing Bayi Hosp, Chinese Peoples Liberat Army Canc Ctr, Nanjing, Jiangsu, Peoples R China
[14] Tianjin Med Univ, Canc Hosp, Tianjin, Peoples R China
[15] Univ Lorraine, INSERM 954, CHU Nancy, Nancy, France
[16] CHU, Serv Hepatogastroenterol, Caen, France
[17] Kindai Univ, Fac Med, Osaka, Japan
[18] Bayer HealthCare SAS, Loos, France
[19] Bayer Vital GmbH, Bayer Pharmaceut, Leverkusen, Germany
[20] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[21] Fourth Mil Med Univ, Xijing Hosp, Affiliated Hosp 1, Xian, Peoples R China
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
O - 009
引用
收藏
页数:1
相关论文
empty
未找到相关数据